MeSH term
Frequency | Condition_Probility | Humans | 32 | 0.0 |
Bridged Compounds/pharmacology | 2 | 20.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Thiones/pharmacology | 2 | 18.0 |
Research Support, Non-U.S. Gov't | 15 | 0.0 |
Adult | 13 | 0.0 |
Aged | 8 | 0.0 |
Female | 15 | 0.0 |
Male | 18 | 0.0 |
Middle Aged | 11 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Animals | 7 | 0.0 |
Comparative Study | 4 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Adolescent | 2 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Rats | 3 | 0.0 |
Somatotropin-Releasing Hormone/*pharmacology | 2 | 2.0 |
Kinetics | 2 | 0.0 |
Growth Hormone/blood/*secretion | 2 | 2.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Glucagon/blood | 4 | 4.0 |
Insulin/*blood | 2 | 1.0 |
Octreotide/*therapeutic use | 6 | 16.0 |
Cloning, Molecular | 2 | 0.0 |
Drug Evaluation | 3 | 1.0 |
Insulin/blood | 4 | 0.0 |
English Abstract | 3 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
Octreotide | 4 | 33.0 |
Acromegaly/blood/*drug therapy | 2 | 14.0 |
Glucose Tolerance Test | 3 | 0.0 |
Growth Hormone/*blood | 2 | 1.0 |
Somatostatin/*analogs & derivatives/therapeutic use | 2 | 18.0 |
